All financings
COMPANY TRANSACTIONS

PMV Pharmaceuticals, Inc.

PMVPNasdaqBiotechnology

Deal details

1 transaction in the database

TRANSACTION REPORT · SEC DISCLOSURES

Deal notes

Not yet verifiedClosing confirmation

Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.

Gross proceeds$50.8M
Offering price$1.21
Discount to prior close0.8%
Warrant coverage100%
Placement agent / underwriterTD Securities (USA) LLC

Transaction overview

01

PMV Pharmaceuticals, Inc. announced a $50.8M underwritten public offering at $1.21 per share. TD Securities (USA) LLC acted as underwriter for the financing.

Financing type
Underwritten Public Offering
Announcement date
Aug 31, 2026
Pricing date
Aug 31, 2026
Closing date
—
Filing date
Sep 2, 2026
Status
Priced
Market cap before announcement
$65.1M
Prior closing price
$1.22
Raise as % of market cap
78%

Market data · FMP

Historical market cap
$65,132,028
Market date
Aug 28, 2026
Closing price
$1.22
Latest reported shares outstanding
53,331,766
Latest reported float shares
48,896,034
Share-data date
Sep 29, 2026

Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.

Financial Modeling Prep ↗

Financing terms

02

Equity

Common shares issued
22,055,000
Price per share
$1.21
Pre-funded warrants
19,900,000
Pre-financing shares disclosed in filing
—
Shares outstanding after financing
—

Investor warrants

Warrant shares
41,955,000
Cash exercise price
$1.21
Term
Five years from issuance; immediately exercisable
Initial exercisability
—
Beneficial ownership limits
—

Fees & transaction economics

03
Placement agent / underwriting fee
6%
Agent fee amount
$3.0M
Management fee
—
Other offering expenses (estimated)
$705,280
Net proceeds (estimated)
$47.0M
Net proceeds as % of gross
92.5%

Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.

Transaction participants

04
Investor names: —

Source documents

05

SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.

424B5 · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
8-K · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
EX-1.1 · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
EX-4.1 · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
EX-4.2 · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
EX-5.1 · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
EX-99.1 · PMV Pharmaceuticals, Inc.SEC filing · Sep 2, 2026
Open source ↗
FMP historical market data · PMVPMarket data · Aug 28, 2026
Open source ↗
424B5 · PMV Pharmaceuticals, Inc.SEC filing · Aug 31, 2026
Open source ↗
SEC deal terms · FMP market data where available · Initial research sample, not complete market coverage. AI-assisted source review; original evidence is available in each report. Names and tickers reflect the transaction date. A dash (—) means the value is unavailable.